Eduardo Magalhães Rego

Professor of Hematology/Oncology, Medical School of Ribeirão Preto, University of São Paulo
Head of the Hematology and Clinical Oncology Service of the University Hospital (HC-FMRP)
Coordinator in Brazil of the International Consortium on Acute Leukemias which is sponsored by the American Society of Hematology
Member of the Board of Directors of the Brazilian Association of Hematology (ABHH)
Editor of the Brazilian Journal of Medical and Biological Research and Associate
Editor of Blood and Annals of Hematology
PubMed Scopus ORCID  ResearcherID Scholar 


1983-1988 Doctor of Medicine (M.D.) Medical School of Ribeirão Preto of the University of São Paulo
1989-1992 Medical Residence/ Fellowship in Hematology, University Hospital, Medical School of Ribeirão Preto of the University of São Paulo
1993-1997 Doctor of Philosophy (Ph.D.) Medical School of Ribeirão Preto of the University of São Paulo
1998-2001 Post-Doctoral Fellowship Memorial Sloan-Kettering Cancer Center, New York, USA
2002 Full Professor, University of São Paulo, USP, Brazil
2005 PhD in Medicine, Fox Chase Cancer Center, FCCC, USA

Research Interests  

Hematological malignancies, in particular acute leukemias
Animal models of acute leukemia
Leukemia and cancer stem cells


Research Overview  

The main focus of our group is to integrate basic and clinical research on acute leukemias, in special acute myeloid leukemias. In order to have a better insight on the molecular basis of leukemogenesis, we have been studying acute promyelocytic leukemia (APL) as a model. We have been addressing the following questions:

1. Which cell subpopulation acts the leukemia initiating cells and how is quiescence and energy generation regulated in this subset;

2. Which microRNAs act as key regulators of differentiation in APL blasts and whether their expression profile are associated with treatment outcome;

3. Does the expression of transcriptinally active and inactive isoforms of the p73 gene affect the response to ATRA and if so how?

4. What is the role of microparticles and annexin II expression in APL-associated coagulopathy;

5. Can the molecular monitoring of the PML/RARA fusion gene using RQ-PCR technology predict relapse better than the routinely used RT-PCR method?;

6. Is leukemia relapse is associated with additional mutagenic events?

7. In leukemia prone syndromes, such as dyskeratosis congenita, which pathways confer survival advantage to hematopoietic progenitors and are associated in malignant transformation. Finally, our group is coordinating in Brazil the International Consortium on APL, which is a trial aiming to improve the treatment outcome of APL patients in developing countries.

Lab Staff  

1. PhD students:
a. Ana Paula A. de L. Lange
b. Antonio R. L. de Araújo
c. Helder Henrique Paiva
d. Sarah Cristina Bassi
2. MsC students:
a. Katarina Holanda
3. Post-docs:
a. Priscila Santos Scheucher
b. Guilherme Augusto Silva dos Santos

Molecular Biology Technicians
Ana Sílvia Gouveia Lima


Andréia M Leopoldino, PhD
Depto de Análises Clínicas, Toxicológicas e Bromatológicas
Faculdade de Ciências Farmacêuticas de Ribeirão Preto Universidade de São Paulo

International Collaborators  

Dr Davide Rugero,
Associate Professor
Helen Diller Family
Cancer Research Center
University of California,
San Francisco (UCSF)
Mission Bay Campus
1450 3rd Street
Room HD 386, MC 3110
San Francisco, CA 94158
Tel: 415/514-9755
Fax: 415/514-4826

Prof. Ellen Solomon,
Prof. David Grimwade,
King’s College London
School of Medicine
Department of Medical and Molecular Medicine
Floor 8 Tower Wing
Guy’s Hospital
London SE1 9RT
Telephone : 0207 1882579

Prof. Hau C.Kwaan,
Marjorie C. Barnett
Professor in Hematology-Oncology
Professor of Medicine
Northwestern University Feinberg School of Medicine
Room 8258, Olson Pavilion
710 N.Fairbanks Court,
Chicago, IL. 60611

Prof. Stefan Bohlander,
Department of Medicine III,
Universität München,
81377 Munich, Germany

Facilities Coordination  

Flow Cytometry and Sorting Facility,
And Small Animals Irradiator Facility,
Medical School of Ribeirão Preto,
University of São Paulo,
FAPESP EMU – grant 09/54218-1

Selected Publications  

1. Dos Santos GA, Abreu E Lima RS, Pestana CR, Lima AS, Scheucher PS, Thomé CH, Gimenes-Teixeira HL, Santana-Lemos BA, Lucena-Araujo AR, Rodrigues FP, Nasr R,Uyemura SA, Falcão RP, de Thé H, Pandolfi PP, Curti C, Rego EM. (+)α-Tocopheryl succinate inhibits the mitochondrial respiratory chain complex I and is as effective as arsenic trioxide or ATRA against acute promyelocytic leukemia in vivo. Leukemia. 2011. doi: 10.1038/leu.2011.216.
2. de Figueiredo-Pontes LL, Assis PA, Santana-Lemos BA, Jácomo RH, Lima AS, Garcia AB, Thomé CH, Araújo AG, Panepucci RA, Zago MA, Nagler A, Falcão RP, Rego EM. Halofuginone has anti-proliferative effects in acute promyelocytic leukemia by modulating the transforming growth factor beta signaling pathway. PLoS One. 2011;6(10):e26713
3. Santana-Lemos BA, de Lima Lange AP, de Lira Benício MT, José TD, Lucena-Araújo AR, Krause A, Thomé CH, Rego EM. The CEBPA gene is down-regulated in acute promyelocytic leukemia and its upstream promoter, but not the core promoter, is highly methylated. Haematologica. 2011;96(4):617-20.
4. Guibal FC, Alberich-Jorda M, Hirai H, Ebralidze A, Levantini E, Di Ruscio A, Zhang P, Santana-Lemos BA, Neuberg D, Wagers AJ, Rego EM, Tenen DG. Identification of a myeloid committed progenitor as the cancer-initiating cell in acute promyelocytic leukemia. Blood. 2009 Dec 24;114(27):5415-25.
5. Barna M, Pusic A, Zollo O, Costa M, Kondrashov N, Rego E, Rao PH, Ruggero D. Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency. Nature. 2008 Dec 18;456(7224):971-5.
6. Yoon A, Peng G, Brandenburger Y, Zollo O, Xu W, Rego E, Ruggero D. Impaired control of IRESmediated translation in X-linked dyskeratosis congenita. Science. 2006 May 12;312(5775):902-6.
7. Rego EM, Ruggero D, Tribioli C, Cattoretti G, Kogan S, Redner RL, Pandolfi PP. Leukemia with distinct phenotypes in transgenic mice expressing PML/RARalpha, PLZF/RAR alpha or NPM/RARalpha. Oncogene. 2006 Mar 23;25(13):1974-9.
8. Rego EM, He LZ, Warrell RP Jr, Wang ZG, Pandolfi PP. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10173-8.